LU90312I2 - S-N-éthyl-3-[(1-diméthyl-amino)éthyl]-N-méthyl-phénylcarbamate ou un sel pharmaceutiquement acceptable de celui-ci en particulier le tartrate hydrogène - Google Patents

S-N-éthyl-3-[(1-diméthyl-amino)éthyl]-N-méthyl-phénylcarbamate ou un sel pharmaceutiquement acceptable de celui-ci en particulier le tartrate hydrogène

Info

Publication number
LU90312I2
LU90312I2 LU90312C LU90312C LU90312I2 LU 90312 I2 LU90312 I2 LU 90312I2 LU 90312 C LU90312 C LU 90312C LU 90312 C LU90312 C LU 90312C LU 90312 I2 LU90312 I2 LU 90312I2
Authority
LU
Luxembourg
Prior art keywords
ethyl
phenylcarbamate
dimethyl
amino
methyl
Prior art date
Application number
LU90312C
Other languages
English (en)
Original Assignee
Proterra Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11055728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90312(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Proterra Ag filed Critical Proterra Ag
Publication of LU90312I2 publication Critical patent/LU90312I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/14—Dithiocarbamic acids; Derivatives thereof
    • C07C333/30—Dithiocarbamic acids; Derivatives thereof having sulfur atoms of dithiocarbamic groups bound to other sulfur atoms
    • C07C333/32—Thiuramsulfides; Thiurampolysulfides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
LU90312C 1985-03-05 1998-11-04 S-N-éthyl-3-[(1-diméthyl-amino)éthyl]-N-méthyl-phénylcarbamate ou un sel pharmaceutiquement acceptable de celui-ci en particulier le tartrate hydrogène LU90312I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL74497A IL74497A (en) 1985-03-05 1985-03-05 Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives

Publications (1)

Publication Number Publication Date
LU90312I2 true LU90312I2 (fr) 1999-01-06

Family

ID=11055728

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90312C LU90312I2 (fr) 1985-03-05 1998-11-04 S-N-éthyl-3-[(1-diméthyl-amino)éthyl]-N-méthyl-phénylcarbamate ou un sel pharmaceutiquement acceptable de celui-ci en particulier le tartrate hydrogène

Country Status (25)

Country Link
US (1) US4948807A (fr)
EP (1) EP0193926B3 (fr)
JP (1) JPS61225158A (fr)
KR (1) KR940010764B1 (fr)
AT (1) ATE58130T1 (fr)
AU (1) AU595504B2 (fr)
CA (1) CA1284501C (fr)
CY (2) CY1748A (fr)
DE (2) DE3675408D1 (fr)
DK (1) DK172851B1 (fr)
ES (1) ES8801193A1 (fr)
FI (1) FI87197C (fr)
GR (1) GR860586B (fr)
HK (1) HK130293A (fr)
HU (1) HU201297B (fr)
IE (1) IE58838B1 (fr)
IL (1) IL74497A (fr)
LU (1) LU90312I2 (fr)
MY (1) MY137602A (fr)
NL (1) NL980031I2 (fr)
NZ (1) NZ215348A (fr)
PH (1) PH23325A (fr)
PL (1) PL146301B1 (fr)
PT (1) PT82127B (fr)
ZA (1) ZA861653B (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH667001A5 (de) * 1985-09-03 1988-09-15 Hugo Degen Untermatratze.
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
US5091583A (en) * 1990-05-07 1992-02-25 Air Products And Chemicals, Inc. Tertiary amine catalysts for polurethanes
IT1271679B (it) * 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
WO1998007431A1 (fr) * 1996-08-22 1998-02-26 New York University Inhibiteurs de la cholinesterase pour le traitement de la maladie de parkinson
ES2208967T3 (es) * 1996-12-18 2004-06-16 Teva Pharmaceutical Industries, Ltd. Derivados de feniletilamina.
PT966435E (pt) 1996-12-18 2005-06-30 Yissum Res Dev Co Derivados aminoindano
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
WO1998031356A1 (fr) * 1997-01-17 1998-07-23 Takeda Chemical Industries, Ltd. Agent combine contenant de l'idebenone pour le traitement de la maladie d'alzheimer
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
JP5558648B2 (ja) * 1998-11-23 2014-07-23 デイビス、ボニー アセチルコリンエステラーゼ阻害剤のための投与製剤
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
ATE374531T1 (de) 2000-01-28 2007-10-15 Martek Biosciences Corp Verstaerkte produktion von lipiden enthaltend mehrfachungesaettigte fettsaeuren durch hochdichte kulturen von eukariotischen mikroben in gaervorrichtungen
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
AU2001249091A1 (en) * 2000-03-03 2001-09-17 Eisai Co. Ltd. Novel methods using cholinesterase inhibitors
WO2001078721A1 (fr) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research Agents de reduction de a$g(b)42
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
WO2003101917A2 (fr) * 2002-05-31 2003-12-11 Sun Pharmaceutical Industries Limited Procede de preparation de phenylcarbamates
USRE42327E1 (en) 2002-06-14 2011-05-03 Toyama Chemical Co., Ltd. Medicinal compositions improving brain function and method for improving brain function
KR20050088992A (ko) 2002-10-07 2005-09-07 더 리전트 오브 더 유니버시티 오브 캘리포니아 아난드아미드 가수분해 차단을 통한 불안감의 조절
CZ293014B6 (cs) * 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
DE10301851A1 (de) * 2003-01-17 2004-07-29 Lts Lohmann Therapie-Systeme Ag Verfahren zur medikamentösen Prophylaxe gegen Vergiftungen durch Cholinesterase-Hemmer, sowie hierfür geeignete Wirkstoffe und Arzneimittel
WO2004071431A2 (fr) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Composition et methode de traitement de troubles neurodegeneratifs
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
EP1651195A4 (fr) * 2003-07-11 2007-10-03 Myriad Genetics Inc Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
US7897639B2 (en) * 2003-10-21 2011-03-01 Colucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
EP1689721B1 (fr) 2003-11-26 2010-07-14 Pfizer Products Inc. Derives d'aminopyrazole en tant qu'inhibiteurs de la gsk-3
GB0329284D0 (en) * 2003-12-18 2004-01-21 Avecia Ltd Process
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
WO2005072713A2 (fr) 2004-01-27 2005-08-11 The Feinstein Institute For Medical Research Inhibiteurs de la cholinesterase pour traiter l'inflammation
AU2005215134B2 (en) * 2004-02-19 2009-01-29 Novartis Ag Use of cholinesterase inhibitors for treating vascular depression
WO2006001877A2 (fr) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
WO2006020853A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
WO2006020852A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
WO2006020850A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
EP1812007B1 (fr) * 2004-11-02 2011-09-07 Northwestern University Composes pyridazine et methodes
WO2006048720A1 (fr) * 2004-11-08 2006-05-11 Emcure Pharmaceuticals Limited Procede efficace de preparation de (s)-3-[(1-dimethyl amino)ethyl]-phenyl-n-ethyl-n-methyl-carbamate
MX2007005137A (es) * 2004-11-23 2007-06-22 Warner Lambert Co Derivados del acido 7-(2h-pyrazol-3-il)-3, 5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de lipidemia.
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8058291B2 (en) * 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
EP1956904B1 (fr) * 2005-12-09 2017-04-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Ladostigil a faible dose pour le traitement du déficit cognitif léger
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
WO2007127474A2 (fr) * 2006-04-28 2007-11-08 Northwestern University Compositions et traitements utilisant des pyridazines et des inhibiteurs de cholinestérase
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
DE602006015241D1 (de) * 2006-08-17 2010-08-12 Alembic Ltd Verbessertes verfahren zur herstellung von rivastigmin
WO2008037433A1 (fr) 2006-09-29 2008-04-03 Synthon B.V. Procédé de fabrication de carbamates d'aminoalkylphényle et intermédiaires de cette fabrication
SG178000A1 (en) 2006-10-27 2012-02-28 Medivation Neurology Inc Methods and combination therapies for treating alzheimer's disease
WO2008097546A2 (fr) * 2007-02-02 2008-08-14 Colucid Pharmaceuticals, Inc. Composés inhibiteurs de cholinestérase
US8013181B2 (en) 2007-04-10 2011-09-06 Dr. Reddy's Laboratories Limited Preparation of rivastigmine and its salts
WO2008124969A1 (fr) * 2007-04-16 2008-10-23 Topharman Shanghai Co., Ltd. Méthode de préparation de rivastigmine et de ses intermédiaires
US7884121B2 (en) 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
CN101795683A (zh) * 2007-07-18 2010-08-04 科露西德医药品公司 用于促进警醒症的方法
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
WO2010023535A1 (fr) 2008-08-25 2010-03-04 Jubilant Organosys Limited Procédé de production de (s)-3-[(1-diméthylamino)éthyl]phényl-n-éthyl-n-méthyl-carbamate par le biais de nouveaux intermédiaires
US8247405B2 (en) 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
CN101580482B (zh) * 2009-05-27 2014-04-23 沈阳药科大学 一种重酒石酸盐卡巴拉汀的制备方法和应用
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CN102134206B (zh) * 2010-01-27 2013-11-20 上海京新生物医药有限公司 一种卡巴拉汀的制备方法
EP2533645B1 (fr) * 2010-02-09 2016-07-27 The Johns Hopkins University Procédés et compositions pour améliorer la fonction cognitive
WO2011151359A1 (fr) 2010-06-02 2011-12-08 Noscira, S.A. Traitement combiné comprenant un inhibiteur de la cholinestérase et un dérivé de thiadiazolidinedione
WO2011151669A1 (fr) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Procédé de production d'un isomère énantiomériquement enrichi d'un dérivé du 3-(1-aminoéthyle) phényle et son utilisation pour produire de la rivastigmine ou son sel pharmaceutiquement acceptable
US8852900B2 (en) 2010-06-17 2014-10-07 Codexis, Inc. Biocatalysts and methods for the synthesis of (S)-3-(1-aminoethyl)-phenol
WO2012131699A1 (fr) 2011-03-30 2012-10-04 Neon Laboratories Ltd. Procédé de préparation de diméthylcarbamate de 3-diméthylaminophényle hautement pur
CN102786441B (zh) * 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
EP2836211B1 (fr) 2012-04-14 2019-03-20 Intra-Cellular Therapies, Inc. Traitement du PTSD et du trouble des impulsions
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
EP2968237A4 (fr) 2013-03-15 2016-08-31 Univ Johns Hopkins Procédés et compositions pour améliorer la fonction cognitive
EP2968220B1 (fr) 2013-03-15 2021-05-05 Agenebio, Inc. Procédés et compositions pour améliorer la fonction cognitive
ES2888074T3 (es) 2013-08-16 2021-12-30 Univ Maastricht Tratamiento del deterioro cognitivo con inhibidor de PDE4
MX384391B (es) 2015-05-22 2025-03-14 Agenebio Inc Composiciones farmacéuticas de levetiracetam de liberación extendida.
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1905990A (en) * 1931-01-02 1933-04-25 Hoffmann La Roche Disubstituted carbamic acid esters of phenols containing a basic constituent
US2208485A (en) * 1937-04-24 1940-07-16 Hoffmann La Roche Process for the manufacture of disubstituted carbamic acid esters of phenols containing a basic substituent
US2362508A (en) * 1940-12-06 1944-11-14 Merck & Co Inc Therapeutic substances
US2493710A (en) * 1947-03-21 1950-01-03 Hoffmann La Roche Carbamic acid esters
DE1037753B (de) * 1956-07-13 1958-08-28 Rohm & Haas Schaedlingsbekaempfungsmittel

Also Published As

Publication number Publication date
DK99186D0 (da) 1986-03-04
NL980031I1 (nl) 1999-01-04
EP0193926B3 (fr) 2010-04-28
HU201297B (en) 1990-10-28
CY2004004I2 (el) 2009-11-04
HUT41718A (en) 1987-05-28
FI860914L (fi) 1986-09-06
KR940010764B1 (ko) 1994-11-11
AU595504B2 (en) 1990-04-05
DE19875046I1 (de) 2003-09-04
GR860586B (en) 1986-07-07
JPS61225158A (ja) 1986-10-06
IE860558L (en) 1986-09-05
FI87197B (fi) 1992-08-31
EP0193926A3 (en) 1987-05-13
EP0193926A2 (fr) 1986-09-10
IL74497A (en) 1990-02-09
NZ215348A (en) 1990-04-26
CA1284501C (fr) 1991-05-28
PT82127A (en) 1986-04-01
ES8801193A1 (es) 1988-01-01
IE58838B1 (en) 1993-11-17
ES552627A0 (es) 1988-01-01
PL146301B1 (en) 1989-01-31
JPH0255416B2 (fr) 1990-11-27
DK172851B1 (da) 1999-08-16
NL980031I2 (nl) 1999-03-01
ATE58130T1 (de) 1990-11-15
MY137602A (en) 2009-02-27
FI87197C (fi) 1992-12-10
PT82127B (pt) 1988-07-01
CY1748A (en) 1994-06-03
PH23325A (en) 1989-07-14
CY2004004I1 (el) 2009-11-04
EP0193926B1 (fr) 1990-11-07
IL74497A0 (en) 1985-06-30
DK99186A (da) 1986-09-06
US4948807A (en) 1990-08-14
HK130293A (en) 1993-12-03
FI860914A0 (fi) 1986-03-04
DE3675408D1 (de) 1990-12-13
AU5428486A (en) 1986-09-11
ZA861653B (en) 1987-10-28
KR860007207A (ko) 1986-10-08

Similar Documents

Publication Publication Date Title
LU90312I2 (fr) S-N-éthyl-3-[(1-diméthyl-amino)éthyl]-N-méthyl-phénylcarbamate ou un sel pharmaceutiquement acceptable de celui-ci en particulier le tartrate hydrogène
AU6576898A (en) Fungicidal trifluorophenyl-triazolopyrimidines
EG18379A (en) Novel pharmacological compounds
MY105344A (en) New sulphonyl compounds
NO981393D0 (no) Guanidinoproteasehemmere
ES461077A1 (es) Procedimiento para la preparacion de 2-bencilpirrolidinas.
IL76345A0 (en) Proline derivatives and antihypertensive and anti-glaucoma pharmaceutical preparations containing the same
PH23506A (en) 1-aralkyl-substituted-1,2,4,-triazole-5-thiols as dopamine- -hydroxylase inhibitors
MY102026A (en) Antiasthmatic.
ES8602021A1 (es) Procedimiento de preparar compuestos espirociclicos antihi- pertensivos
MX9204642A (es) 1,4-dihidropiridinas con actividad paf-antagonista
ES8608887A1 (es) Procedimiento para la obtencion de preparados combinados antihipertensores y antianginicos a base de dihidropiridina y bloquear beta.
ES8401488A1 (es) Procedimiento de preparacion de derivados de diaza-3,7a-cicloherta-(j,k)-fluorenos.
FI880999L (fi) Litium-litiumnitrid-anod.
AU476756B2 (en) PHARMACOLOGICALLY ACTIVE 4, 8-DIMETHOXY-FURO-(3',2'-F) BENZOXAZOL-2-yl ACETHYDROXAMIC ACID
AU6816787A (en) (Gem-heterocyclodimethanamine-N,N') platinum complexes
SU1297428A1 (ru) 54, 56:58, 60-дииндий (iii) дихлор-6, 11:19, 24:32, 37:45, 50-тетраимино-5-, 52:13, 18:20, 31:39, 44-тетранитрилоктабензо [с, д, е, р, и, у, d, h] (1, 10, 19, 28) - тетраазациклогексатриаконтин как полупроводник
UA11675A1 (uk) 1-БЕtА-ОКСИЕТИЛАМІHО-3-КЕТО-5,5-ДИМЕТИЛЦИКЛОГЕКСЕH -1, ЯКИЙ МАЄ АHАЛЬГЕТИЧHУ АКТИВHІСТЬ
JPS5283520A (en) Novel 2-arylthio-cyclopentanones
IT8501203A0 (it) Apparecchiatura per la diffusione audio-video-stampa di messaggi di utilita'pubblica.
SU1045566A1 (ru) Хлорангидрид 3,4-дициано - 4′- -карбоксидифенилоксида в качестве полупродукта для синтеза тетранитрилов ароматических тетракарбоновых кислот, тетранитрилы ароматических тетракарбоновых кислот как мономеры для синтеза полигексазоцикланов и полигексазоцикланы как материалы для электропроводящих покрытий
SU1297421A1 (ru) ГИДРОХЛОРИДЫ 3-ЗАМЕЩЕННЫХ 2-ЭТИЛ-4-МЕТИЛПИРАЗОЛО(1,5-а)-БЕНЗИМИДАЗОЛА, ОБЛАДАЮЩИЕ АНТИАРИТМИЧЕСКОЙ АКТИВНОСТЬЮ
HUT45553A (en) Stabil, liquide, washing-cleaning composition containing enzymes
SU1075674A1 (ru) 2,3,2,3-Тетрагидро-3,3-тетрацианметилен-5,5-бис-as-триазин, обладающий противовоспалительной и анальгетической активностью